Short description
Isabl develops cancer diagnostic tests based on whole genome and RNA sequencing data.
Description
Isabl is a startup developing cancer whole-genome and RNA sequencing diagnostic assays. Founded in 2020 after incubating its technology at MSKCC from 2015 to 2019, Isabl joined the Winter 2020 batch of Y Combinator. The company secured $3M in seed funding from Two Sigma Ventures, Y Combinator, and BoxOne Ventures. Isabl received the FDA Breakthrough Device designation in 2021, a nod to the transformative nature of its cancer diagnostic tests. Further establishing its credibility, Isabl was granted a direct-to-phase-2 SBIR $2M grant from the NCI to advance Isabl GxT, a specialized test targeting pediatric and rare solid cancers. Under the leadership of founders Dr. Elli Papaemmanuil, Dr. Andrew Kung, and Juan Medina, Isabl's team combines deep expertise in precision medicine, computational biology, and software engineering with a strong track record in biomarker discovery and clinical decision support.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
New York, New York, United States, North America
Founded on
January 1, 2020
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Cannot Access, Noaccess, Nopepepe, Cannot Access
Sign in for full access
Founders
Andrew Kung, Elli Papaemmanuil, Juan Medina